title: Half-match bone marrow transplants may raise odds for more recipients.
authors.forename: Karyn
authors.initials: K
authors.lastname: Hede
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D018952:Antigens, CD34; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D000074301:CD52 Antigen; D002985:Clinical Protocols; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005434:Flow Cytometry; D006023:Glycoproteins / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D019520:Living Donors; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D014411:Neoplastic Stem Cells / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D019653:Myeloablative Agonists; D000074323:Alemtuzumab; D003520:Cyclophosphamide